Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00440245|
Recruitment Status : Recruiting
First Posted : February 26, 2007
Last Update Posted : October 30, 2018
|Condition or disease||Intervention/treatment||Phase|
|Asthma COPD||Drug: salbutamol||Phase 4|
In asthma, the administration (inhalation) of a selective β2 receptor agonist (e.g. salbutamol), prior to methacholine challenge has been shown to shift the dose response curve to the right and "bronchoprotect" the airway against airway smooth muscle contraction. The extent of β2 receptor agonist bronchoprotection in COPD is unknown.
Airway hyperresponsiveness (AHR) to direct acting agents such as histamine and methacholine is a feature of both asthma and COPD. In asthma, the abnormality leading to AHR is believed to be due to changes in airway smooth muscle (e.g. hypertrophy, hyperplasia, contractile apparatus) whereas in COPD the AHR is likely due to structural or geometric changes.
The investigators hypothesize that the bronchoprotection afforded by salbutamol against methacholine challenge will be greater in asthma than in COPD due to differences in underlying airway abnormalities.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Bronchoprotection of Salbutamol in Asthma and COPD|
|Study Start Date :||February 2007|
|Estimated Primary Completion Date :||August 2019|
|Estimated Study Completion Date :||August 2019|
There are two groups, asthma and COPD, which are being compared with respect to bronchoprotection from an active treatment (salbutamol).
200 micrograms salbutamol from MDI
- methacholine PC20 dose shift [ Time Frame: one hour ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00440245
|Contact: Beth Davis, PhDfirstname.lastname@example.org|
|University of Saskatchewan||Recruiting|
|Saskatoon, Saskatchewan, Canada, S7N0W8|
|Contact: Beth Davis, PhD 306-844-1444 email@example.com|
|Principal Investigator: Donald Cockcroft, MD|
|Principal Investigator:||Donald Cockcroft, MD||University of Saskatchewan|